Colorectal Neoplasm Clinical Trial
Official title:
A Phase I and Pharmacokinetic Study of S-1 Combined With Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy
This study is an open-label, single center, and a dose-escalating phase I study to determine the maximal tolerated dose and the recommended dose of S-1 combined with irinotecan/oxaliplatin in patients with unresectable or metastatic colorectal or gastric carcinoma.
Dose level and escalating schedule are followings;
- S-1 (level 1/2, 3/4, 5/6: 60, 70, 80 mg/m2/day) every 12-h p.o. on days 1(evening)-15
(morning)
- Irinotecan (level 1,2/3, 4/5, 6: 120, 130, 140, 150 mg/m2) mixed in d5w or normal
saline 500 ml iv over 90 min on day 1
- Oxaliplatin 85 mg/m2 fixed dose mixed in d5w 250 ml iv infusion over 2-h on day 1
Treatment will be administered every 3 weeks. Start at dose level 1. Thereafter, dose level
2, 3, 4, 5, and 6. If dose-limiting toxicity (DLT) occurs at dose level 1, dose level at -1
will follow
Dose escalation will be continued until more than one-third of the patients in a given
cohort show dose-limiting toxicity (DLT) during treatment cycle 1. At least three patients
will be enrolled in each cohort. Before escalating to the next dose level, all three
patients should have received at least one treatment cycle. If none of the first three
treated patients develops DLT in the first cycle at a specific dose level, dose escalation
will be continued. If one of the first three treated patients develops DLT at any dose
level, then three additional patients are to be entered on the same dose level. If only one
in six patients at a given level experiences a DLT, escalation will proceed. The MTD is
defined as the dose level at which at least one-third of patients experienced a DLT. The RD
for the subsequent phase II study is defined as the preceding dose level before the MTD is
attained. Intra-patient dose escalation will not be permitted. Treatment will be continued
in the absence of disease progression or unacceptable toxicity with maximum 12 cycles. For
purpose of determining the MTD, only DLT occurring during the first cycle of therapy will be
considered.
DLTs are defined as any of following;
- Grade 4 neutropenia lasting at least 7 days or grade 3 or 4 neutropenia associated with
fever 38.3C as single axillary temperature or 38 C for 1-h
- Grade 4 thrombocytopenia
- Grade 3 or 4 non-hematological toxicity except alopecia, and nausea/vomiting
- Grade 3 or 4 nausea/vomiting not reduced to grade 1 with aggressive antiemetic support
- Inability of the patient to take 75% of the planned chemotherapy dose during the
treatment period
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02244632 -
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01417611 -
The Usefulness of I-scan in Screening Colonoscopy
|
N/A | |
Completed |
NCT02057471 -
Intravenous Iron: Measuring Response in Anemic Surgical Patients
|
Phase 4 | |
Terminated |
NCT01074333 -
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
|
N/A | |
Recruiting |
NCT05953662 -
Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer
|
N/A | |
Completed |
NCT01959269 -
Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
|
N/A | |
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT04160832 -
Prevalence and Spectrum of Cancer Susceptibility Among Patients With Advanced Colorectal Polyps
|
||
Terminated |
NCT02961283 -
Study of ASN003 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Suspended |
NCT02121405 -
Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM
|
Phase 3 | |
Active, not recruiting |
NCT03936530 -
Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer
|
||
Terminated |
NCT03724071 -
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02882620 -
Enhancing Prevention Pathways Toward Tribal Colorectal Health
|
N/A | |
Completed |
NCT00906997 -
Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy
|
N/A | |
Completed |
NCT00188331 -
Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy
|
N/A | |
Completed |
NCT04786704 -
A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population
|
||
Terminated |
NCT02384850 -
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT01288833 -
Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study
|
N/A | |
Completed |
NCT00001693 -
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
|
Phase 1 | |
Recruiting |
NCT03280407 -
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
|
Phase 2 |